Market Place
Sourcing Support
Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
22 Mar 2022 //
REUTERS
Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia
01 Mar 2021 //
PRNASIA
Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal
01 Mar 2021 //
PHARMAFILE
Oasmia AB Signs Phase 1b Trial Agreement with SAKK, The Swiss Group
08 Jun 2020 //
PRESS RELEASE
Oasmia Pharmaceutical announces poster presentation at ASCO
14 May 2020 //
PRESS RELEASE
Oasmia announces outcome of review to deliver long-term, profitable growth
13 May 2020 //
PRESS RELEASE
Oasmia receives upfront payment of 20 MUSD from Elevar
21 Apr 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.